COTA

Learn how COTA is helping providers validate AI applications with real-world data. Link in comments 👇 #realworlddata #oncologyresearch #healthcareAI

COTA, PreciseDx, and Baptist Health will present the results of their study validating the results of the novel AI test, PreciseBreast at predicting breast cancer recurrence during Poster Session 2 on December 11. Read the full announcement: https://lnkd.in/eNUNqnnW San Antonio Breast Cancer Symposium #SABCS24 #healthcareAI #realworlddata

Attending #ASH24 this weekend?? Look out for the COTA team - and better yet - come to our reception tonight! Register now to reserve your spot: https://lnkd.in/eU2ZaNzH

AI is a beacon of hope when it comes to fixing the US healthcare system. But we're still figuring out how to validate that the information it generates is accurate. In fact, FDA commissioner Robert Califf included this as one of his 4 major concerns when it comes to healthcare AI. In a study that will be presented at San Antonio Breast Cancer Symposium, COTA worked with Miami Cancer Institute at Baptist Health to validate that the AI-enabled, faster, and less expensive, PreciseBreast™, is equivalent to the widely used Oncotype DX test at predicting breast cancer recurrence. For the retrospective study, we looked at 425 patients and ultimately found similar results between PreciseBreast™ and Oncotype DX. According to the CEO of PreciseDx (maker of PreciseBreast™): “With the ultimate goal of providing care decision support data that works seamlessly in the pathology workflow, returns results in less than 48 hours and costs a fraction of the current technology, PreciseBreast™ optimizes, and could ultimately replace, gene-expression testing.” And COTA's chief medical officer C. K. Wang, MD: “The way I look at it is that, in the future, we're not just going to see this explosion of AI limited to the diagnostic space—I suspect that we will see penetration of AI into every facet of the patient care journey,” Wang said. “And so every step, or every tool that’s developed, will need to be validated on real world data to make sure that it’s actually performing correctly.” Read more in Fierce Biotech: https://lnkd.in/eiAwTVf3 #rwd #realworlddata #oncologyresearch #sabcs24

Attend COTA's reception at #ASH24 where you can: ✅ Connect with our network of hematologic oncology experts ✅ Take in beautiful views of San Diego from our rooftop venue ✅ Enjoy craft cocktails and delicious bites ✅ Receive a gift bag (👀 comments 👇) for the first 30 attendees RSVP today: https://lnkd.in/eU2ZaNzH

How do we deliver the highest quality data to power your cancer research? According to our partners at Precision Health Informatics, LLC, a Texas Oncology subsidiary: ☝ 𝘊𝘖𝘛𝘈 𝘩𝘢𝘴 𝘢 𝘷𝘦𝘳𝘺, 𝘷𝘦𝘳𝘺 𝘴𝘵𝘳𝘰𝘯𝘨 𝘮𝘦𝘥𝘪𝘤𝘢𝘭 𝘰𝘯𝘤𝘰𝘭𝘰𝘨𝘺 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘬𝘯𝘰𝘸𝘭𝘦𝘥𝘨𝘦 𝘣𝘢𝘴𝘦, 𝘢𝘯𝘥 𝘵𝘩𝘦𝘺 𝘢𝘳𝘦 𝘢𝘣𝘭𝘦 𝘵𝘰 𝘭𝘰𝘰𝘬 𝘢𝘵 𝘳𝘦𝘤𝘰𝘳𝘥𝘴 𝘵𝘰 𝘮𝘢𝘬𝘦 𝘳𝘦𝘤𝘰𝘮𝘮𝘦𝘯𝘥𝘢𝘵𝘪𝘰𝘯𝘴 𝘵𝘰 𝘶𝘴 𝘸𝘩𝘦𝘳𝘦 𝘵𝘩𝘦𝘳𝘦 𝘮𝘢𝘺 𝘣𝘦 𝘥𝘢𝘵𝘢 𝘨𝘢𝘱𝘴 ✌ 𝘞𝘦 𝘩𝘢𝘷𝘦 𝘵𝘩𝘦 𝘭𝘰𝘸𝘦𝘴𝘵 𝘢𝘵𝘵𝘳𝘪𝘵𝘪𝘰𝘯 𝘳𝘢𝘵𝘦 𝘸𝘪𝘵𝘩 𝘊𝘖𝘛𝘈. 𝘚𝘰, 𝘵𝘩𝘢𝘵 𝘮𝘦𝘢𝘯𝘴 𝘪𝘧 𝘸𝘦 𝘴𝘦𝘯𝘥 𝘰𝘷𝘦𝘳 100 𝘳𝘦𝘤𝘰𝘳𝘥𝘴, 𝘵𝘩𝘦𝘺'𝘳𝘦 𝘶𝘴𝘪𝘯𝘨 87 𝘰𝘧 𝘵𝘩𝘰𝘴𝘦 𝘳𝘦𝘤𝘰𝘳𝘥𝘴 -- 𝘸𝘪𝘵𝘩 𝘯𝘰 𝘮𝘪𝘴𝘴𝘪𝘯𝘨 𝘥𝘢𝘵𝘢 𝘦𝘭𝘦𝘮𝘦𝘯𝘵𝘴 -- [𝘵𝘰 𝘤𝘰𝘯𝘵𝘳𝘪𝘣𝘶𝘵𝘦] 𝘵𝘰 𝘢 𝘴𝘵𝘶𝘥𝘺. 𝘛𝘩𝘢𝘵'𝘴 𝘦𝘯𝘰𝘳𝘮𝘰𝘶𝘴𝘭𝘺 𝘩𝘪𝘨𝘩, 𝘴𝘰𝘮𝘦 𝘰𝘵𝘩𝘦𝘳 𝘱𝘰𝘵𝘦𝘯𝘵𝘪𝘢𝘭 𝘱𝘢𝘳𝘵𝘯𝘦𝘳𝘴 𝘵𝘩𝘢𝘵 𝘗𝘏𝘐 𝘪𝘯𝘪𝘵𝘪𝘢𝘭𝘭𝘺 𝘤𝘰𝘯𝘴𝘪𝘥𝘦𝘳𝘦𝘥 𝘩𝘢𝘥 𝘢𝘵𝘵𝘳𝘪𝘵𝘪𝘰𝘯 𝘳𝘢𝘵𝘦𝘴 𝘢𝘳𝘰𝘶𝘯𝘥 50%, 𝘯𝘰𝘵𝘦𝘥 Lori Brisbin-Ferraro, 𝘊𝘖𝘖 𝘢𝘵 𝘗𝘏𝘐 𝘢𝘯𝘥 𝘝𝘗 𝘰𝘧 𝘗𝘳𝘦𝘤𝘪𝘴𝘪𝘰𝘯 𝘔𝘦𝘥𝘪𝘤𝘪𝘯𝘦 𝘢𝘵 𝘛𝘦𝘹𝘢𝘴 𝘖𝘯𝘤𝘰𝘭𝘰𝘨𝘺 Read more in Xtelligent Healthcare (link in comments👇) #realworlddata #rwd #oncologyresearch

Thank you for supporting our efforts to bring clarity to cancer care with real-world data, analytics, and AI. We wish everyone who celebrates a happy Thanksgiving and look forward to seeing many of you in San Diego at #ASH24 next weekend. COTA will be closed on Thursday and Friday. 💜

Going to the American Society of Hematology (ASH) conference in San Diego? COTA and Memorial Sloan Kettering Cancer Center will present the findings from their research collaboration on Diffuse Large B-Cell Lymphoma (DLBCL) studies in older patients. The joint-research explores the implication of treatment urgency and end-of-life care patterns for older DLBCL patients and provides new findings that demonstrate the potential for RWD to improve cancer care plans for an older, often ignored patient demographic. #ASH24 #ASH2024 #realworlddata #rwd

COTA and Memorial Sloan Kettering Cancer Center will present new research at the American Society of Hematology Annual Meeting (ASH) next month. The joint-research explores the implication of treatment urgency and end-of-life care patterns for older patients with Diffuse Large B-Cell Lymphoma (DLBCL). It provides new findings that demonstrate the potential for RWD to improve cancer care for older adults - an often ignored patient demographic. Read more in Clinical Trials Arena. Link in comments 👇 #ash24 #ash2024 #oncologyresearch #RealWorldData #RWD

COTA and Memorial Sloan Kettering Cancer Center will present the findings from their research collaboration on Diffuse Large B-Cell Lymphoma (DLBCL) studies in older patients at the upcoming American Society of Hematology Annual Meeting (ASH) next month. The joint-research explores the implication of treatment urgency and end-of-life care patterns for older DLBCL patients and provides new findings that demonstrate the potential for RWD to improve cancer care plans for an older, often ignored patient demographic. Key takeaways: ▶️ DLBCL is a blood cancer that is commonly diagnosed in the elderly ▶️ Survival rates drop dramatically with advancing age ▶️ Age, comorbidities, risk and physical ability may prevent older individuals from participating in clinical trials  ▶️ This exclusion means we lack clear insight into the care and outcomes of older individuals ▶️ RWD offers critical insights into treatment patterns for older patient populations ▶️ RWD sheds new light on older patients’ response to emerging treatments and how best to manage end-of-life care and outcomes Key research findings: ◀️ Older adults with DLBCL who initiated treatment immediately after diagnosis had worse outcomes and shorter overall survival rates compared to patients who had a longer interval between diagnosis and first-line therapy ◀️ Only a minority of older adults with DLBCL had a documented hospice or palliative care referral ◀️ There is a need for additional research to understand the value of (or lack thereof) care delivered near the end-of-life for these patients According to C. K. Wang, MD., chief medical officer at COTA: “Clinical trials have largely excluded the elderly population which has resulted in uncertainty as to the right treatment approaches for this patient population. Additionally, we know that hospice care tends to be under utilized in the US, especially in cancer patients. Using technologies powered by real-world data, we can bridge this gap to ensure that older adults receive evidence-based care during a critical time in their life.” According to Paul Hamlin, MD, Medical Director, David H. Koch Center for Cancer Care, and Attending, Lymphoma Service - Division of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center: “The incorporation of real-world data to assess outcomes in older patients is an invaluable resource, given their general decreased representation in clinical trials. The data being presented as ASH 2024 regarding the DTI interval (Diagnosis to Treatment Interval) and the utilization of hospice/palliative care referrals can help inform future trials and identifies ongoing gaps in our knowledge/practices.” Read the full announcement on our website: cotahealthcare[dot]com #ASH2024 #ASH24 #RWD #RealWorldData #OncologyResearch #CancerResearch #DLBCL #MSK